(Q37926255)

25 August 2017

title

Adjunctive lacosamide in clinical practice: sodium blockade with a difference? (English)

1 reference

25 August 2017

4

Martin J Brodie

0 references

Linda J Stephen

1

object named as

Linda J Stephen

0 references

author name string

Linda J Stephen

1

1 reference

25 August 2017

Kevin Kelly

2

1 reference

25 August 2017

Pamela Parker

3

1 reference

25 August 2017

Martin J Brodie

4

1 reference

25 August 2017

publication date

3 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

22

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

499-504

1 reference

Lacosamide: a review of preclinical properties.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Improving the reporting of pragmatic trials: an extension of the CONSORT statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Combining antiepileptic drugs--rational polytherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

A prospective audit of adjunctive zonisamide in an everyday clinical setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Patterns of treatment response in newly diagnosed epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Medical genetics: a marker for Stevens-Johnson syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

Valproate and sodium currents in cultured hippocampal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.07.035

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEBEH.2011.07.035

1 reference

25 August 2017

1 reference